Sang-Woo Park
Algemeen Directeur bij NKMAX CO., LTD.
Vermogen: 671 775 $ op 31-05-2024
Profiel
Mr. Sang-Woo Park is a Chairman & Chief Executive Officer at Nkmax Japan, Inc., a Chairman & Chief Executive Officer at Atgen Japan, a Chairman & Chief Executive Officer at Nkmax H&D Co. Ltd., a Chairman & Chief Executive Officer at coAsia Biotech Corp., a Chief Executive Officer at Atgen H&D, a Chairman & Chief Executive Officer at ATGen America, Inc., a Chairman & Chief Executive Officer at ATGen Canada, Inc., a Chairman & Chief Executive Officer at NKMAX Co., Ltd.
(South korea) and a Chairman & Chief Executive Officer at NKMAX Co., Ltd.
He is on the Board of Directors at NKGen Biotech, Inc. Mr. Park was previously employed as a Chief Executive Officer & Director by J way Co., Ltd.
He also served on the board at NKGen Biotech, Inc. /US/.
He received his undergraduate degree from Korea University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
1.60% | 29-04-2024 | 397 378 ( 1.60% ) | 663 621 $ | 31-05-2024 |
NKMAX CO., LTD.
0.01% | 26-01-2024 | 5 418 ( 0.01% ) | 8 154 $ | 31-03-2024 |
Actieve functies van Sang-Woo Park
| Bedrijven | Functie | Begin |
|---|---|---|
| NKMAX CO., LTD. | Algemeen Directeur | 31-03-2023 |
| ATGen America, Inc. | Algemeen Directeur | 01-02-2014 |
| ATGen Canada, Inc. | Algemeen Directeur | 01-09-2013 |
Atgen H&D
 Atgen H&D Pharmaceuticals: OtherHealth Technology Atgen H&D develops protein products. Sang-Woo Park has been the CEO of the South Korean company since 2016. | Algemeen Directeur | 01-01-2016 |
NKMAX Co., Ltd.
 NKMAX Co., Ltd. Pharmaceuticals: MajorHealth Technology NKMAX Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following business divisions: Immunity Cell Cure, Immunodiagnosis Kit, Health Functional Foods, and Bio Research. The company was founded on January 14, 2002 and is headquartered in Seongnam-si, South Korea. | Algemeen Directeur | 01-01-2002 |
| Nkmax H&D Co. Ltd. | Algemeen Directeur | 01-06-2016 |
coAsia Biotech Corp.
 coAsia Biotech Corp. BiotechnologyHealth Technology Part of NKMAX Co., Ltd. (South Korea), coAsia Biotech Corp. manufactures biological products. Sang-Woo Park has been the CEO of the Thai company since 2016. coAsia Biotech was acquired by NKMAX Co., Ltd. (South Korea) on February 28, 2018 for $0.10 million. | Algemeen Directeur | 01-04-2016 |
| Atgen Japan | Algemeen Directeur | 01-09-2017 |
| Nkmax Japan, Inc. | Algemeen Directeur | 01-11-2017 |
Eerdere bekende functies van Sang-Woo Park
| Bedrijven | Functie | Einde |
|---|---|---|
| ░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░ ░░░ ░░░░ ░░░░ | ░░░░░░░░ ░░░░░░░░░ | - |
Opleiding van Sang-Woo Park
| Korea University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| J WAY CO., LTD. | Consumer Services |
| NKMAX CO., LTD. | Health Technology |
| Bedrijven in privébezit | 9 |
|---|---|
| ATGen Canada, Inc. | |
| ATGen America, Inc. | |
Atgen H&D
Atgen H&D Pharmaceuticals: OtherHealth Technology Atgen H&D develops protein products. Sang-Woo Park has been the CEO of the South Korean company since 2016. | Health Technology |
NKMAX Co., Ltd.
NKMAX Co., Ltd. Pharmaceuticals: MajorHealth Technology NKMAX Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following business divisions: Immunity Cell Cure, Immunodiagnosis Kit, Health Functional Foods, and Bio Research. The company was founded on January 14, 2002 and is headquartered in Seongnam-si, South Korea. | Health Technology |
coAsia Biotech Corp.
coAsia Biotech Corp. BiotechnologyHealth Technology Part of NKMAX Co., Ltd. (South Korea), coAsia Biotech Corp. manufactures biological products. Sang-Woo Park has been the CEO of the Thai company since 2016. coAsia Biotech was acquired by NKMAX Co., Ltd. (South Korea) on February 28, 2018 for $0.10 million. | Health Technology |
| Nkmax H&D Co. Ltd. | |
| Atgen Japan | |
NKGen Biotech, Inc.
 NKGen Biotech, Inc. BiotechnologyHealth Technology NKGen Biotech, Inc. is a biotechnology company which engages in harnessing the immune system through natural killer cell therapies. It develops a proprietary stabilizing peptide, monoclonal antibodies, and recombinant proteins for research use. The company was founded in 2002 and is headquartered in Santa Ana, CA. | Health Technology |
| Nkmax Japan, Inc. |
